Investor Relations

Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder. Catalyst's lead candidate, Firdapse^TM for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III study. Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement disorders associated with the treatment of Parkinson's Disease.

Annual Reports & Proxy Statement

View all » Recent Releases

05/16/13
Catalyst Pharmaceutical Partners Reports First Quarter 2013 Financial Results

04/02/13
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2012 Financial Results

View all »Events & Presentations

05/17/13 at 11:00 AM
Antiepileptic Drug Trials XII Conference Presentation

03/19/13 at 1:00 PM ET
Catalyst Pharmaceutical Partners to Present at 25th Annual ROTH Conference

^ Top